Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Brooks Laboratories Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Brooks Laboratories şirketinin toplam hissedar öz sermayesi ₹655.9M ve toplam borcu ₹56.4M olup, bu da borç-öz sermaye oranını 8.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹904.5M ve ₹248.6M dir. Brooks Laboratories 'in FAVÖK'ü ₹17.5M faiz karşılama oranı 2.1 dur. Şirketin ₹6.9M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

8.6%

Borç/özkaynak oranı

₹56.42m

Borç

Faiz karşılama oranı	2.1x
Nakit	₹6.93m
Eşitlik	₹655.85m
Toplam yükümlülükler	₹248.60m
Toplam varlıklar	₹904.45m

Son finansal sağlık güncellemeleri

Recent updates

Would Brooks Laboratories (NSE:BROOKS) Be Better Off With Less Debt?

Sep 28

Does Brooks Laboratories (NSE:BROOKS) Have A Healthy Balance Sheet?

Jun 10

Estimating The Intrinsic Value Of Brooks Laboratories Limited (NSE:BROOKS)

Feb 22

Is Brooks Laboratories (NSE:BROOKS) Using Too Much Debt?

Dec 08

Is Brooks Laboratories (NSE:BROOKS) A Risky Investment?

Jul 07

Here's Why Brooks Laboratories (NSE:BROOKS) Can Afford Some Debt

Jan 05

Brooks Laboratories (NSE:BROOKS) Is Making Moderate Use Of Debt

Sep 22

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BROOKS 'nin kısa vadeli varlıkları ( ₹310.5M ) kısa vadeli yükümlülüklerini ( ₹230.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: BROOKS şirketinin kısa vadeli varlıkları ( ₹310.5M ) uzun vadeli yükümlülüklerini ( ₹18.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BROOKS 'nin net borç/öz sermaye oranı ( 7.5% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: BROOKS 'nin borç/öz sermaye oranı son 5 yılda 26.9% seviyesinden 8.6% seviyesine düştü.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: BROOKS şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: BROOKS un, serbest nakit akışı her yıl % 17.6 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Brooks Laboratories Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Would Brooks Laboratories (NSE:BROOKS) Be Better Off With Less Debt?

Does Brooks Laboratories (NSE:BROOKS) Have A Healthy Balance Sheet?

Is Brooks Laboratories (NSE:BROOKS) Using Too Much Debt?

Is Brooks Laboratories (NSE:BROOKS) A Risky Investment?

Here's Why Brooks Laboratories (NSE:BROOKS) Can Afford Some Debt

Brooks Laboratories (NSE:BROOKS) Is Making Moderate Use Of Debt

Recent updates

Brooks Laboratories Limited Announces Board Appointments

New minor risk - Share price stability

High number of new and inexperienced directors

Brooks Laboratories Limited, Annual General Meeting, Sep 19, 2024

First quarter 2025 earnings released: ₹0.94 loss per share (vs ₹1.81 loss in 1Q 2024)

Brooks Laboratories Limited to Report Q1, 2025 Results on Aug 14, 2024

New minor risk - Share price stability

Full year 2024 earnings released: ₹7.67 loss per share (vs ₹8.46 loss in FY 2023)

Third quarter 2024 earnings released: ₹1.51 loss per share (vs ₹2.03 loss in 3Q 2023)

Brooks Laboratories Limited to Report Q3, 2024 Results on Jan 31, 2024

Second quarter 2024 earnings released: ₹0.64 loss per share (vs ₹3.19 loss in 2Q 2023)

Brooks Laboratories Limited Announces Director Appointments

Brooks Laboratories Limited, Annual General Meeting, Sep 21, 2023

Brooks Laboratories Limited, Annual General Meeting, Sep 21, 2023

New minor risk - Shareholder dilution

Brooks Laboratories Limited Approves the Appointment of Bhushan Singh Rana as an Additional Director (Executive)

First quarter 2024 earnings released: ₹1.81 loss per share (vs ₹3.80 loss in 1Q 2023)

Brooks Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023

Brooks Laboratories Limited Appoints Durga Shankar Maity as Additional Director

Third quarter 2023 earnings released: ₹2.03 loss per share (vs ₹3.14 loss in 3Q 2022)

Brooks Laboratories Limited Appoints Kaushalya Singh as a Whole Time Director of the Company

Brooks Laboratories Limited Announces Resignation of Atul Ranchal as Chairman, Effective on November 23, 2022

Would Brooks Laboratories (NSE:BROOKS) Be Better Off With Less Debt?

Brooks Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023

First quarter 2023 earnings released: ₹3.80 loss per share (vs ₹0.47 loss in 1Q 2022)

Does Brooks Laboratories (NSE:BROOKS) Have A Healthy Balance Sheet?

Full year 2022 earnings released: ₹7.82 loss per share (vs ₹7.84 loss in FY 2021)

Jyoti Sancheti Resigns as Company Secretary & Compliance Officer of Brooks Laboratories Limited, with Effect from 7 June, 2022

Brooks Laboratories Limited to Report Q4, 2022 Results on May 30, 2022

Estimating The Intrinsic Value Of Brooks Laboratories Limited (NSE:BROOKS)

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Brooks Laboratories Limited to Report Q3, 2022 Results on Feb 14, 2022

Is Brooks Laboratories (NSE:BROOKS) Using Too Much Debt?

Second quarter 2022 earnings released: ₹1.97 loss per share (vs ₹1.35 profit in 2Q 2021)

Less than half of directors are independent

Technical Director & Whole Time Director Suresh Garg has left the company

Insufficient new directors

Is Brooks Laboratories (NSE:BROOKS) A Risky Investment?

Full year 2021 earnings released: ₹7.76 loss per share (vs ₹13.84 loss in FY 2020)

Third quarter 2021 earnings released: ₹1.03 loss per share (vs ₹1.67 loss in 3Q 2020)

New 90-day low: ₹58.60

Brooks Laboratories Limited to Report Q3, 2021 Results on Feb 11, 2021

Here's Why Brooks Laboratories (NSE:BROOKS) Can Afford Some Debt

New 90-day high: ₹73.20

New 90-day high: ₹71.75

New 90-day high: ₹68.75

Brooks Laboratories (NSE:BROOKS) Is Making Moderate Use Of Debt

Brooks Laboratories Limited to Report Q4, 2020 Results on Jul 30, 2020

First quarter earnings released

New 90-day high: ₹44.65

Brooks Laboratories Limited to Report Q1, 2021 Results on Sep 15, 2020

Full year earnings released - ₹13.84 loss per share

New 90-day high - ₹37.80

Full year earnings released - ₹13.84 loss per share

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin